EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, Vanda Pharmaceuticals's Enterprise Value is $-85.5 Mil.
Vanda Pharmaceuticals's Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2023 was $12.4 Mil. Therefore, Vanda Pharmaceuticals's EV-to-FCF for today is -6.89.
The historical rank and industry rank for Vanda Pharmaceuticals's EV-to-FCF or its related term are showing as below:
VNDA'
s EV-to-FCF Range Over the Past 10 Years
Min: -205.86 Med: -3.23 Max: 1365.38
Current: -6.89
During the past 13 years, the highest EV-to-FCF of Vanda Pharmaceuticals was 1365.38. The lowest was -205.86. And the median was -3.23.
VNDA's EV-to-FCF is ranked better than 98.97% of 390
companies
in the Biotechnology industry
Industry Median: 6.365
vs VNDA: -6.89
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Vanda Pharmaceuticals's EV-to-FCF
For the Biotechnology subindustry, Vanda Pharmaceuticals's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Vanda Pharmaceuticals's EV-to-FCF Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Vanda Pharmaceuticals's EV-to-FCF distribution charts can be found below:
* The bar in red indicates where Vanda Pharmaceuticals's EV-to-FCF falls into.
Vanda Pharmaceuticals's current Enterprise Value is $-85.5 Mil.
Vanda Pharmaceuticals's Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $12.4 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
Vanda Pharmaceuticals's PE Ratio for today is calculated as:
Vanda Pharmaceuticals's share price for today is $5.04.
Vanda Pharmaceuticals's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.052.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.
Vanda Pharmaceuticals EV-to-FCF Related Terms
Thank you for viewing the detailed overview of Vanda Pharmaceuticals's EV-to-FCF provided by GuruFocus.com. Please click on the following links to see related term pages.
Vanda Pharmaceuticals (Vanda Pharmaceuticals) Business Description
Vanda Pharmaceuticals Inc is a biopharmaceutical company engaged in the development and commercialization of therapies to address high unmet medical needs and improve the lives of patients. Its commercial portfolio comprises two products, HETLIOZ for the treatment of Non-24-Hour Sleep-Wake Disorder (Non-24) & nighttime sleep disturbances in Smith-Magenis Syndrome (SMS) and Fanapt for the treatment of schizophrenia. Its other products include VHX-896 and ASO Molecules. The majority of revenue is derived from HETLIOZ product sales.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
VNDA has been successfully added to your 